

6. References

1. *Priority List of Adverse Events of Special Interest: COVID-19*. 2020 5/25/2020 [cited 2020 11/12/2020]; Available from: https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf.
2. Shimabukuro, T. *Enhanced safety monitoring for COVID-19 vaccines in early phase vaccination*. 2020 9/22/2020 [cited 2020 1/12/2020]; Available from: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-09/COVID-03-Shimabukuro.pdf>.
3. *Coronavirus Disease 2019 (COVID-19)*. 2020 5/13/2020 11/8/2020]; Available from: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>.
4. Wang, C., et al., *A novel coronavirus outbreak of global health concern*. *The Lancet*, 2020. **395**(10223): p. 470-473.
5. Prevention, C.f.D.C.a., *CDC Confirms Possible Instance of Community Spread of COVID-19 in U.S.* 2020.
6. *COVID-19 Dashboard*. 2020 [cited 2020 12/15/2020]; Available from: <https://coronavirus.jhu.edu/map.html>
7. *United States COVID-19 Cases and Deaths by State*. 2020 [cited 2020 11/8/2020]; Available from: https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days.
8. *Development and Licensure of Vaccines to Prevent COVID-19*. 2020 June 2020; Available from: <https://www.fda.gov/media/139638/download>.
9. Nelson, J.C., et al., *Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data*. *Pharmacoepidemiology and Drug Safety*, 2012. **21**: p. 62-71.
10. Greene, S.K., et al., *Near real-time vaccine safety surveillance with partially accrued data*. *Pharmacoepidemiology and Drug Safety*, 2011. **20**(6): p. 583-590.
11. Leite, A., N.J. Andrews, and S.L. Thomas, *Near real-time vaccine safety surveillance using electronic health records—a systematic review of the application of statistical methods*. *Pharmacoepidemiology and Drug Safety*, 2016. **25**(3): p. 225-237.
12. Jackson, L.A., et al., *An mRNA vaccine against SARS-CoV-2—preliminary report*. *New England Journal of Medicine*, 2020.
13. Pfizer, *PFIZER AND BIONTECH ANNOUNCE EARLY POSITIVE DATA FROM AN ONGOING PHASE 1/2 STUDY OF MRNA-BASED VACCINE CANDIDATE AGAINST SARS-COV-2* 2020.
14. Dodd, C.N., et al., *International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines*. *Vaccine*, 2013. **31**(40): p. 4448-4458.
15. Schonberger, L.B., et al., *Guillain-Barré syndrome following vaccination in the national influenza immunization program, United States, 1976–1977*. *American Journal of Epidemiology*, 1979. **110**(2): p. 105-123.
16. Wijnans, L., et al., *Bell's palsy and influenza(H1N1)pdm09 containing vaccines: A self-controlled case series*. *PLoS One*, 2017. **12**(5): p. e0175539.
17. Rüggeberg, J.U., et al., *Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data*. *Vaccine*, 2007. **25**(31): p. 5675-5684.
18. Su, J.R., et al., *Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016*. *Journal of Allergy and Clinical Immunology*, 2019. **143**(4): p. 1465-1473.
19. Pellegrino, P., et al., *Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems*. *PloS one*, 2013. **8**(10): p. e77766.
20. Duffy, J., et al., *Narcolepsy and influenza A (H1N1) pandemic 2009 vaccination in the United States*. *Neurology*, 2014. **83**(20): p. 1823-1830.

